|
|
SV40 Pathogenesis of Human Infections
|
5R01CA104818-04
|
$464,495
|
$232,248
|
BUTEL, JANET
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
1P30CA125123-01
|
$1,500,000
|
$15,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-01S1
|
$111,700
|
$1,117
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Training Patients and Partners for HSCT: A Novel Coping Skills Intervention
|
1R03CA130725-01
|
$84,500
|
$84,500
|
Lawsin, Catalina
|
BERNARD M. BARUCH COLLEGE
|
|
|
Pathogenesis of Notch Leukemia
|
5R01CA082308-09
|
$433,640
|
$108,410
|
ASTER, JON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
An Ets2 dependent stromal restriction of breast cancer
|
5R01CA098778-05
|
$324,050
|
$162,025
|
OSHIMA, ROBERT
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA030199-27
|
$3,387,817
|
$33,878
|
VUORI, KRISTIINA
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
|
|
Enhancing Activity of Alkylating Agents in Neuroblastoma
|
5R01CA082830-06
|
$62,346
|
$20,574
|
REYNOLDS, CHARLES
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
|
Gene Transfer to Facilitate Dose-Intensification in the Treatment of Pediatric B*
|
5R21CA121578-02
|
$206,823
|
$206,823
|
Wagner, Lars
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-03
|
$279,026
|
$139,513
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
|
Determinants of Relapse Risk After BMT for ALL
|
1R01CA116660-01A2
|
$304,189
|
$304,189
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
|
USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
|
5R01CA102646-03
|
$308,531
|
$154,266
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
|
Peptide Vaccine To Prevent CMV Disease After HSCT
|
3R01CA077544-09S1
|
$107,242
|
$107,242
|
Diamond, Don
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Peptide Vaccine To Prevent CMV Disease After HSCT
|
5R01CA077544-09
|
$466,660
|
$466,660
|
Diamond, Don
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Hematopoietic Cell Transplantation for Hematologic Malignancies
|
3P01CA030206-25S1
|
$89,324
|
$89,324
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Hematopoietic Cell Transplantation for Hematologic Malignancies
|
5P01CA030206-25
|
$2,776,839
|
$2,776,839
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
City of Hope Lymphoma SPORE
|
5P50CA107399-04
|
$2,163,323
|
$540,831
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
A Standardized Nursing Intervention Protocol for HCT Patients
|
5R01CA107446-02
|
$417,565
|
$417,565
|
GRANT, MARCIA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA033572-24S1
|
$61,920
|
$21,053
|
KRONTIRIS, THEODORE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA033572-24S2
|
$103,852
|
$35,310
|
KRONTIRIS, THEODORE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA033572-24
|
$2,274,248
|
$773,244
|
KRONTIRIS, THEODORE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors
|
2P01CA043904-16A1
|
$2,922,793
|
$876,838
|
RAUBITSCHEK, ANDREW
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
CD8+ HELPER-INDEPENDENT T CELLS IN TUMOR THERAPY
|
5R01CA089511-07
|
$293,771
|
$73,443
|
COHEN, PETER
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
|
CONTINUOUS CELL SORTING BY MAGNETOPHORESIS
|
5R01CA062349-14
|
$347,791
|
$208,675
|
Zborowski, Maciej
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
|
Host-Tumor Cell Interactions in Myeloma:
|
5P01CA078378-10
|
$2,008,736
|
$662,883
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Role of Cytokines in Myeloma Pathogenesis
|
5R01CA050947-16
|
$283,743
|
$42,561
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-43S1
|
$124,531
|
$3,736
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-43S3
|
$137,869
|
$4,136
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-43S4
|
$232,326
|
$6,970
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-43S5
|
$250,000
|
$7,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-43
|
$11,526,509
|
$345,795
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Rebuilding Immunity for Survival
|
5U19CA100265-04
|
$2,730,410
|
$2,730,410
|
NADLER, LEE
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Novel Approaches to Stem Cell Transplantation
|
5P01CA047741-15
|
$1,686,422
|
$1,129,903
|
Chao, Nelson
|
DUKE UNIVERSITY
|
|
|
Duke Comp Cancer Ctr Core Support Grant
|
3P30CA014236-33S1
|
$84,062
|
$4,203
|
LYERLY, HERBERT
|
DUKE UNIVERSITY
|
|
|
Duke Comp Cancer Ctr Core Support Grant
|
5P30CA014236-33
|
$6,558,287
|
$327,914
|
LYERLY, HERBERT
|
DUKE UNIVERSITY
|
|
|
Graft Engineering and Immunotherapy After Unrelated Cord Blood Transplantation
|
1R01CA132110-01
|
$304,000
|
$304,000
|
Szabolcs, Paul
|
DUKE UNIVERSITY
|
|
|
Functions of E2A in B Lymphocyte Development
|
5R01CA072433-10
|
$310,291
|
$31,029
|
Zhuang, Yuan
|
DUKE UNIVERSITY
|
|
|
Separating Antitumor & GvHD in Allogeneic T-Cells
|
5R01CA074364-08
|
$298,849
|
$298,849
|
Waller, Edmund
|
EMORY UNIVERSITY
|
|
|
Adult Leukemia Research Center
|
2P01CA018029-32
|
$5,086,500
|
$5,086,500
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Radiation Sensitivity, DNA Repair and Second Cancers
|
5R01CA102542-04
|
$254,400
|
$254,400
|
FRIEDMAN, DEBRA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
HPV: Biology, Clinical Significance and Epidemiology
|
2P01CA042792-19A1
|
$1,958,158
|
$979,079
|
GALLOWAY, DENISE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Immunosupression-Resistant Gene Modified Donor T Cells
|
5R01CA109381-03
|
$323,970
|
$323,970
|
GEORGES, GEORGE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-34S1
|
$103,800
|
$14,532
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-34S3
|
$237,500
|
$33,250
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer Center Support Grant (Comprehensive)
|
5P30CA015704-34
|
$9,881,120
|
$1,383,357
|
HARTWELL, LELAND
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Emotional Expression and Cancer Caregivers
|
5R21CA112477-02
|
$178,493
|
$89,247
|
Langer, Shelby
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Improving Outcomes Assessment in Chronic GVHD
|
1U01CA118953-01A1
|
$763,255
|
$763,255
|
LEE, STEPHANIE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Mycophenylate mofetil for treatment of chronic GVHD
|
5R01CA098906-05
|
$361,338
|
$361,338
|
MARTIN, PAUL
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Clinical Significance of MHC Haplotypes in HCT
|
5R01CA100019-05
|
$318,037
|
$318,037
|
Petersdorf, Effie
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies
|
5P01CA044991-20
|
$1,865,350
|
$1,119,210
|
Press, Oliver
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Total relevant funding to Organ Transplantation Research for this search: $71,467,297
|
